← Evidence map

ArticleOncogene2026

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Yifeng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | OpenQuestion